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Abstract
Concentrations of soluble c-erbB-2 were determined in
the sera of 64 patients with distant metastasis from
advanced breast cancer receiving second-line hormone
or chemotherapy in comparison to 35 breast cancer
patients without detectable recurrent disease and 17
healthy blood donors. The sera of non-metastatic breast
cancer patients contained s-erbB-2 concentrations simi-
lar to those of healthy blood donors. Patients with distant
metastasis from advanced breast cancer had significant-
ly higher values of s-erbB-2 in comparison to patients
with non-disseminated disease (mean: 59.6 vs. 11.6 U/
ml; p = 0.022). A significant correlation was observed
between s-erbB-2 serum levels and serum LDH concen-
trations (p ! 0.001), levels of alkaline phosphatase (p !
0.001), and the presence of hepatic metastasis (p =
0.001). Time to tumor progression was significantly
shorter in patients with s-erbB-2 levels above 40 U/ml
(mean: 23.4 vs. 56.7 months; p = 0.002). Furthermore,
breast cancer patients with hepatic metastasis and those
with elevated s-erbB-2 serum levels above 40 U/ml had
limited response to hormone or chemotherapy. Non-
responders had significantly higher s-erbB-2 levels
(mean: 270.3, range: 42–500 U/ml;) compared with the
responder group (mean: 23.1, range: 0–149 U/ml; p !
0.001). Logistic regression analysis indicated that ele-
vated s-erbB-2 serum levels above 40 U/ml independent-
ly predicted an unfavorable response to second-line hor-
mone or chemotherapy in patients with advanced meta-
static breast cancer.
Copyright © 2002 S. Karger AG, Basel
Introduction
HER-2/c-erbB-2 is the human homologue of the rat
neu oncogene and was originally identified in rat neuro-
blastomas. The c-erbB-2 oncogene encodes for a 185-kD
transmembrane receptor with tyrosine kinase activity
which is closely related to the epidermal growth factor
receptor. Recent findings indicate that activation of the
HER-2 receptor is mediated by heterodimerization with
receptors of the HER1, HER3, HER4 growth factor
receptor family following ligand binding [1]. Amplifica-
tion of the c-erbB-2 gene and overexpression of the pro-
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tein is associated with a poor prognosis in breast cancer
patients [2–4]. Inhibition of erbB-2 activity by an anti-
HER-2 monoclonal antibody was shown to enhance che-
mosensitivity against tumor cells and improve clinical
response rates in patients with metastatic HER/neu-over-
expressing breast cancer [5–8].
The extracellular domain of the c-erbB-2 oncoprotein
is released from tumor cells by proteolytic cleavage and
detectable in supernatants of erbB-2-overexpressing tu-
mor cell lines [9–12]. Determination of serum levels of
shed c-erbB-2 oncoprotein in breast cancer patients
showed increased soluble erbB-2 levels in patients with
advanced breast cancer [13–17] associated with reduced
response to adjuvant or neoadjuvant hormone or chemo-
therapy [18, 19]. In patients with metastatic disease, ele-
vated serum erbB-2 levels or erbB-2 overexpression in the
tumor were associated with decreased response to first-
line hormone or chemotherapy [20] or second-line hor-
mone therapy [21]. However, in the study reported by
Revillion et al. [22], levels of c-erbB-2 were not related to
the response to chemotherapy in patients with advanced
breast cancer.
Tumor progression following first-line hormone or
chemotherapy is a major problem in patients with meta-
static breast cancer. Predictive markers giving further
information concerning the probable response regarding
different treatment strategies would be of clinical interest.
We have therefore determined soluble erbB-2 serum lev-
els in an unselected group of patients with metastatic
breast cancer receiving second-line hormone or chemo-
therapy in comparison to breast cancer patients without
recurrent disease or healthy blood donors.
Serum levels of erbB-2 were compared with clinicopa-
thologic parameters (e.g. patient age), parameters of the
original primary tumor (e.g. tumor size), histopatholog-
ical grading, nodal status, estrogen and progesterone re-
ceptor levels and serum levels of lactate dehydrogenase
(LDH), alkaline phosphatase (ALP), time to tumor pro-
gression, the number of metastasized organs or presence
of liver metastases.
Patients and Methods
Soluble human erbB-2 levels were measured by an ELISA pur-
chased from Dianova (Hamburg, Germany). Serum samples were
examined from 99 breast cancer patients with or without recurrent
disease treated at the Departments of Internal Medicine III and Sur-
gery, Klinikum Grosshadern, University of Munich, Germany. In
addition, soluble erbB-2 levels were determined in serum samples
from healthy blood donors. Serum samples were divided into ali-
quots and stored at –70°C until analysis was performed.
In 72 breast cancer patients, a modified radical mastectomy with
lymphadenectomy was performed. Patients with small tumors
(!2 cm) and in the absence of contraindications (multifocal tumors,
high intraductal component, lobular carcinomas or small breast vol-
ume) were treated by segmentectomy with lymphadenectomy and
postoperative radiotherapy. Patients with lymph-node-positive tu-
mors received an adjuvant hormone or chemotherapy (tamoxifen or
cyclophosphamide, methotrexate and fluorouracil, CMF) in relation
to their menopausal status. Patients developing distant metastasis
during the follow-up were treated by first-line chemotherapy (usually
CMF).
At the time of investigation, 35 breast cancer patients were with-
out recurrent disease, while 64 had progressive disease with metas-
tases located in the liver (n = 11), lung (n = 8), bone (n = 21) or at
multiple sites (n = 24). All patients with metastatic disease received
second-line hormone or chemotherapy because of tumor progression
or relapse after an initial hormone or chemotherapy for metastatic
disease. Response to hormone or chemotherapy was evaluated by
WHO/UICC criteria.
The responder group included patients with complete or partial
remission and patients with stable disease/no change, while non-
responders were patients with progressive disease showing objective
criteria for tumor progression of at least 25%. Thirty-eight patients
received anti-estrogen therapy (usually tamoxifen), while 26 patients
were treated by chemotherapy (Adriamycin plus cyclophosphamide
or CMF). Response to therapy was evaluated after 6 months of treat-
ment. Objective response to therapy (complete and partial responses)
or no change was observed in 35/64 (54.7%) patients investigated.
Patients with locoregional tumor recurrences with or without distant
metastases treated by surgery or local radiotherapy with or without
additional hormone or chemotherapy were not included in the
study.
Data were evaluated by ANOVA for comparison of mean values,
the Wilcoxon test for nonparametric data and the ¯2 test or Fisher's
exact test. Results are expressed as means B SEM. Box blot diagrams
show median levels with lower/upper quartiles and maximum/mini-
mum values. All p values reported are two sided. Logistic regression
was performed using diadochotomized variables using the following
cutoff levels for each variable determined in a healthy control group
(mean +2 SD): LDH 240 U/ml; ALP 175 U/ml, and soluble erbB-2
40 U/ml. In some patients parameters related to the primary tumor
were not completely available (especially lymph node involvement or
grading).
Results
We analyzed the sera of 35 non-metastatic and 64
breast cancer patients with progressive metastatic disease
for soluble erbB-2 concentrations and evaluated their
response to second-line hormone or chemotherapy. Lev-
els of soluble erbB-2 were not related to parameters of the
initial primary tumor, such as tumor invasion, lymph
node involvement, grading or levels of estrogen or proges-
terone receptors (table 1). A significant correlation was
observed between s-erbB-2 serum levels and serum LDH
concentrations (p ! 0.001), levels of alkaline phosphatase
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Table 1. Soluble c-erbB-2 serum levels in correlation to clinical and
histopathologic parameters
Parameters Soluble c-erbB-2, U/ml
mean B SEM p
Primary tumor
T 1/2
T 3/4
41.5B11.6
46.3B20.6 NS
N negative
N positive
35.8B15.4
46.1B13.2 NS
G 2
G 3
27.5B12.8
75.4B25.8 0.076
ER ^  20 fmol/mg 58.6B16.5 NSER 120 fmol/mg 17.0B2.0
PgR ^  20 fmol/mg 58.0B15.9 NSPgR 120 fmol/mg 13.8B1.4
Progressive disease
Age !50 years
650 years
35.8B15.6
45.9B12.9 NS
TTPr !24 months
624 months
104.3B35.6
32.7B8.5
0.026
LDH !240 U/ml
1240 U/ml
21.0B4.1
120.0B47.8
!0.001
ALP !175 U/ml
6175 U/ml
21.0B4.1
120.1B47.8 
!0.001
Metastasis 1 organ
11 organ
56.6B20.5
64.8B22.4 NS
Non hepatic met. 24.42B4.5 0.001
Hepatic metastasis 131.86B41.8
Various clinical and histopathological parameters were correlated
with the absence or presence of metastatic breast cancer disease. For
quantitative or qualitative parameters, the mean values or percent-
ages were calculated.
TTPr = Time to tumor progression; ER = estrogen receptor;
PgR = progesterone receptor; NS = not significant.
(p ! 0.001), and the presence of hepatic metastasis (p =
0.01). Time to tumor progression was significantly re-
duced in patients with s-erbB-2 levels above 40 U/ml
(mean: 23.4 vs. 56.7 months; p = 0.002).
Sera of non-metastatic breast cancer patients con-
tained s-erbB-2 concentrations similar to those of healthy
blood donors (mean: 9.2 U/ml, n = 17). In patients with
distant metastasis from recurrent breast cancer, signifi-
cantly higher values of s-erbB-2 were detected in compari-
son to patients with non-disseminated disease (mean val-
ues: 59.6 vs. 11.6 U/ml; p = 0.022, table 2, fig. 1).
To investigate the predictive value of soluble erbB-2
levels regarding the response to therapy, CD44v6 levels
determined in 64 patients with advanced metastatic
breast cancer at the beginning of second-line hormone or
Table 2. Determination of various clinical and histopathological
parameters in patients with and without metastatic breast cancer
Characteristics Breast cancer patients
non-metastatic
mean B SEM n
metastatic
mean B SEM n
p
Primary tumor
T 1/2
T 3/4
26
9
46
18 NS
N negative
N positive
12
23
22
26 NS
G 2
G 3
24
11
22
32 NS
ER, fmol/mg 48.7B8.9 58.48B14.7 NS
PgR, fmol/mg 97.3B25.5 43.48B16.7 NS
Progressive disease
Age, years 54.2B1.8 55.5B1.3 NS
LDH, U/ml 147.9B4.6 235.7B22.6 0.013
ALP, U/ml 93.5B4.7 205.8B30.8 0.005
s-erbB-2, U/ml 11.6B0.7 59.6B15.2 0.022
ER = Estrogen receptor; PgR = progesterone receptor; NS = not
significant.
chemotherapy were related to the response to therapy.
Responsiveness to therapy was assessed by WHO/UICC
criteria. Patients with metastatic disease were divided
into two groups, one with positive erbB-2 serum levels
(above 40 U/ml) and the other with negative erbB-2
serum levels (below 40 U/ml). The frequency of respond-
ers was 32/38 (84.2%) in the group with low soluble erbB-
2 levels and 3/26 (11.5%; p ! 0.001) in the group of
patients with high erbB-2 serum levels. As shown in
table 3, patients not responding to second-line hormone
or chemotherapy had elevated mean levels of LDH (446.8
vs. 190.5 U/ml; p = 0.001) or ALP (334.8 vs. 187.8 U/ml;
p = 0.015), increased levels of s-erbB-2 (270.3 vs. 23.1 U/
ml; p ! 0.001; fig. 2) and more frequently hepatic metasta-
sis (18/29 vs. 8/35; p = 0.01) in comparison to the
responder group. So far, we did not observe differences in
the response to therapy between the patients treated eith-
er by hormone or chemotherapy with respect to erbB-2
serum levels.
Logistic regression analysis including LDH, ALP, pres-
ence of hepatic metastasis and soluble erbB-2 levels (1 40
U/ml) as variables indicated that only elevated s-erbB-2
serum levels above 40 U/ml independently predicted an
unfavorable response to second-line hormone or chemo-
therapy (p = 0.001) in patients with recurrent metastatic
breast cancer.
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Fig. 1. Levels of s-erbB-2 were determined
in the sera of breast cancer patients followed
up after tumor resection: 35 patients were
without distant metastasis (non-metastatic),
while 64 patients had developed metastases
in the liver, bones, lungs or at multiple sites.
Fig. 2. Levels of soluble erbB-2 are shown in
patients without evidence of clinical re-
sponse to hormone or chemotherapy for
metastatic breast cancer (non-responder
group; n = 29) in comparison to patients with
objective criteria of response to therapy (re-
sponder group; n = 35).
Table 3. Correlation between response to
therapy and clinical and histopathological
parameters
Characteristics Responder
mean n
Non-responder
mean n
p
Primary tumor
T 1/2
T 3 / 4
25
10
21
8 NS
N negative
N positive
14
12
6
14 NS
G 2
G 3
14
16
8
16 NS
ER, fmol/mg 88.4 (0–549) 41.1 (0–283) NS
PgR, fmol/mg 73.52 (0–742) 7.7 (0–30) NS
Progressive disease
Age, years 54.3 (34–76) 55.3 (39–75) NS
TTPr, months 52.7 (0–233) 24.1 (2–62) NS
LDH, U/ml 190.5 (119–430) 446.8 (135–1219) 0.001
ALP, U/ml 187.8 (0–1,452) 334.8 (124–514) 0.015
s-erbB-2, U/ml 23.1 (0–149) 270.3 (42–500) !0.001
Metastases
1 organ
11 organ
23
12
17
12 NS
Hepatic
Non-hepatic
8
27
18
11 0.01
For abbreviations, see table 1. Ranges in parentheses.
Discussion
Progressive metastatic disease is a major problem in
patients with breast cancer. Predictive factors would be of
clinical interest to indicate the probability of a favorable
response to various treatment modalities. However, few
data are available investigating the predictive value of
tumorbiologic factors regarding the response to second-
line therapy in breast cancer patients with advanced met-
astatic disease. Estrogen and progesterone receptor levels
were reported to define the response to hormone therapy
in patients with advanced breast cancer [23]. Foekens et
1 2
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al. [24] have shown a poor response to tamoxifen therapy
in patients with recurrent breast cancer and overexpres-
sion of the urokinase-type plasminogen activator and its
inhibitor PAI-1. The amplification of the HER-2/neu
oncogene leading to c-erbB2 protein overexpression and
increased serum levels was implicated in several studies
with early tumor recurrence, poor prognosis [2–4, 13–17]
and unfavorable response to first-line endocrine therapy
[18, 19] in breast cancer patients.
Based on the study of Leitzel et al. [21] reporting a cor-
relation between serum erbB-2 levels and the response to
second-line hormone therapy in metastatic breast cancer,
we analyzed soluble erbB-2 levels in patients with ad-
vanced metastatic disease receiving second-line hormone
or chemotherapy. Our data indicate an unfavorable re-
sponse to second-line hormone or chemotherapy in pa-
tients with progressive metastatic breast cancer and ele-
vated serum erbB-2 levels. Increased erbB-2 serum levels
were additionally associated with clinical signs of progres-
sive malignant disease as indicated by reduced time to
tumor progression and the presence of liver metastasis.
Therefore, these breast cancer patients with advanced
metastatic disease do not seem to profit from standard
hormone or chemotherapy.
However, the results of other studies investigating the
role of serum erbB-2 levels regarding the response to adju-
vant or first-line chemotherapy in breast cancer patients
are controversial. These reports [25, 26] seem to indicate
an improved response to adjuvant or first-line chemother-
apy in breast cancer patients with elevated erbB-2 levels
using doxorubicin, CMF and paclitaxel as chemothera-
peutic substances. In contrast, other studies indicate an
association of elevated soluble erbB-2 levels with unre-
sponsiveness of advanced breast cancer patients to anthra-
cyclines or CMF treatment [4, 20]. Furthermore, Colomer
et al. [27] have shown in a prospective study the predictive
value of circulating HER2/erbB-2 levels in patients with
advanced breast cancer associated with reduced efficacy
to first-line paclitaxel-doxorubicin-based chemotherapy.
Based on the results of previous reports and our study, we
conclude that tumor progression following first-line che-
motherapy might select breast cancer subtypes with erbB-2
overexpression leading to reduced responsiveness to sec-
ond-line chemotherapy even by substances reported to be
effective during adjuvant or first-line treatment. There-
fore, analysis of soluble erbB-2 in the sera of breast cancer
patients with advanced disease and tumor progression fol-
lowing first-line chemotherapy might be of predicitive val-
ue to select patient subgroups with unfavorable response to
standard hormone or chemotherapy.
Although the treatment of patients with metastatic
breast cancer with monoclonal antibodies against the
p185 c-erbB-2 oncoprotein alone or in combination with
various chemotherapy protocols was reported to improve
response to therapy and patient outcome [5–8], recent
experimental evidence has shown reduced efficacy of
anti-erbB-2 antibodies in the treatment of tumor cells
with high levels of shed s-erbB-2, due to neutralizing
effects [28].
Therefore, the selection of patients with low serum lev-
els of shed erbB-2 might be relevant to improve the
response to anti-erbB-2 antibody treatment. Further-
more, new strategies are needed to improve the clinical
outcome of these patients. These might include attempts
to specifically target the immunogenic profile of tumors
with erbB-2 overexpression [29, 30] or modify the recep-
tor-activated tyrosine kinase signal by specific inhibitors
or interaction with proteins involved in negative receptor
regulation [1, 31].
Elevated levels of soluble erbB-2 were associated with
a reduced time to tumor progression. However, based on
our study, we cannot conclude that elevated s-erbB-2
serum levels might predict an early relapse following first-
line therapy for metastatic disease. Prospective studies
will have to investigate the predictive role of s-erbB-2 lev-
els during the follow-up of patients with advanced breast
cancer with respect to tumor progression and prognosis.
Our analysis of soluble erbB-2 levels in patients with
advanced metastatic breast cancer receiving standard
hormone or chemotherapy indicates that the determina-
tion of erbB-2 serum levels seems to be of predictive value
with respect to response to therapy. However, further
innovative treatment strategies will be necessary to im-
prove the outcome of these patients with advanced meta-
static breast cancer and otherwise poor prognosis.
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